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Abstract
Normal aging begins after 60 years of age. According to Harman, the accumulation of
free radicals, which results from weakening of repair and protective mechanisms, takes
place in the aging brain. It is believed that especially in the population of the most elderly
there is increased incidence of both dementia and depression. The causes of these central
nervous system disorders in the aging human body are changes at the molecular level,
such as  changes  in  the  biochemical  parameters,  the  accumulation of  mutations  in
nuclear and mitochondrial DNA, and epigenetic changes. Biomarkers associated with
aging  of  the  brain  include  accumulated  deposits  of  β-amyloid  (Aβ),  disturbed
cholesterol  homeostasis,  altered  neuroimaging  parameters,  and  impaired  glucose
metabolism. Genetic factors are also responsible for normal aging, for example, SIRT1,
AKT1, and CDKN1A, and among them the longevity genes, such as FOXO3A and CETP.
Dementia as well as cognitive decline may be modified by poly-T variants of TOMM40
and APOE alleles via influencing the level of apolipoprotein E (apoE) in the brain and
in the plasma as well as by its ability of Aβ clearance.
Identifying  the  molecular  factors  associated  with  aging  and  dementia  may  help
introduce new approaches to preventing geriatric disorders, including depression and
dementia.
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1. Introduction
Currently, average life expectancy in the world is over 60 years. The world’s longest life
expectancy is in Japan, at 82.2 years, and in Australia, at 80.6 years. In Europe, the longest-
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lived people are the French, at 80.6 years, the Swedes, at 80.6 years, the Italians, at 79.9 years,
the Greeks, at 79.3 years, the Dutch, at 79.1 years, and the Germans, at 78.9 years. It is predicted
that in Europe from 2005 to 2050, the number of people following into their 80th year of life
will increase by 43 million [1].
In psychological studies on the elderly, three subperiods were stratified among people over
60 years old; these included young olds (65–75 years of age), old olds (75–85 years old), and eldest
olds (over 85 years of age). Deterioration of cognitive functions was visible in the eldest olds age
group, while asymptomatic structural changes in the brain, such as cortical atrophy, poli- and
leukoaraiosis (deterioration of white matter, present in 8–90% of the elderly with no signs of
dementia), or decreased glucose metabolism and deteriorated subcortical and cortical flow,
could be detected by neuroimaging even among the young olds [2].
Progressive aging of the population is one of the factors determining the increasingly frequent
occurrence of cognitive impairment and dementia syndromes. Dementia, due to its prevalence
in the population (it occurs in approximately 10% of those 65 years of age and in approximately
30–40% of those 90 years of age), requires great concern and clinical care. It is estimated that
by 2040, the number of elderly people with dementia in the world will exceed 80 million [3].
According to the classification of mental disorders in the American Psychiatric Association’s
DSM – IV (Diagnostic and Statistical Manual of Mental Disorders) [4], there is no isolated,
separate diagnostic category for “dementia,” but the criteria for this diagnosis are contained
in the various types of dementia, for example, Alzheimer’s disease (AD), vascular dementia
(VD), or in other diseases. According to these criteria, a diagnosis of dementia is necessary to
determine the presence of multiple cognitive deficits that cause significant disturbances in the
functioning of social exclusion and mental illness (depression) and delirium.
Dementia is a progressive impairment of the functional status and significantly reduces the
quality of life of older people in all its dimensions, since physical disability and the loss of
sphincter control coexist along with dementia. The most common cause of dementia in the
oldest patients is the degenerative process that is underway in the brain in the course of AD.
In old age, an important process associated with the degeneration of neurons in AD is cerebral
arteriosclerosis. Dementia, with dying neurons, is caused by both pathologies. A high per‐
centage of the causes of dementia in the elderly may develop depression. In these patients, the
following is observed especially often: loss of interest, sleep disturbances, psychomotor
disturbances, and problems with concentration. In turn, the use of multiple drugs in dementia
complicates the diagnosis of depression [4].
Depression is defined as an emotional distress syndrome (states of depressed mood, depres‐
sion), which is often co-morbid with somatic diseases and/or with intensifying their symptoms.
Depression is a common and serious problem among the elderly and increases mortality.
Approximately 15% of people over the age of 65 have symptoms of depression, which impede
daily functioning [2, 4].
It is believed that the functional and cognition changes observed in older persons are associated
with disturbances at the molecular level in the aging body. Molecular changes in the aging
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process may relate to genomic instability as a result of accumulation of mutations, telomere
attrition and epigenetic alterations, and alteration in the level of brain biomarkers [2].
To select significant studies for this review, the authors conducted multiple searches through
public databases, including PubMed and Scopus, by using the following search strategy:
(“normal aging” or “aging”) and (“dementia” or “cognitive decline”) and (“biomarker” or
“SNP” or “genetic polymorphism” or “mutation”). The last search was performed in February
2016. A subsequent data mining through review articles and references facilitated finding
additional eligible studies.
2. Brain biomarkers and cognitive function in normal aging
Central changes leading to impaired brain and cognition functions have been reported in
normal brain aging, but data are inconclusive [5, 6]. A study [5] using functional magnetic
resonance imaging (MRI) with gadolinium contrast confirmed changes in the hippocampus
associated with impairment of cognitive function in elderly people. Also, a study conducted
on 564 cognitively normal individuals (average age was 78 years) using MRI and fluorodeox‐
yglucose positron emission tomography (FDG-PET) and Pittsburgh Compound B (PiB) PET
indicated impairment of cognition and imaging biomarkers. The causes of these central
changes in the brain of the aged subjects seem to have been increased β-amyloid (Aβ) levels
[6]. In the senescent brain, accumulation of Aβ deposits is eminent, in the form of senile plaques
as well as fibrillary tangles in the neurons. The lesions may develop in the human brain as late
as in one’s 80s (frequently with no signs of dementia). The slower the accumulation of lesions
is, the longer the time period required to develop dementia [7, 8]. Cerebral amyloidosis has
been associated not only with Aβ deposition but also with higher pulse pressure in the presence
of neurodegeneration, which may lead to more rapid progression of dementia [9]. However,
more recent data indicate that Aβ deposition may in time exceed brain structural changes, such
as grey matter volume, as measured by MRI, and neuronal hypometabolism assessed using
PET with 18F-fluorodeoxyglucose (FDG) [10]. Moreover, the cognitive decline in elderly
patients is associated with brain infarcts [11]. Also dietary factors, such as ω-3 polyunsaturated
fatty acids (PUFAs), were shown to be associated with normal brain function; the PUFA
concentration remains in reverse correlation with brain atrophy in cognitively normal elders
[10].
3. Molecular changes in normal aging and dementia
In the aging process, the epigenetic changes lead to expression alteration of genes associated
with vital functions of cells, such as mitochondrial function, as well as protective and repair
mechanisms, as shown in Table 1.
One of genetic hallmarks of aging is genomic instability which includes accumulation of
genetic damage both in nuclear DNA (nDNA) and mitochondrial DNA (mtDNA). mtDNA is
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more susceptible to DNA damaging factors than nDNA due to its oxidative environment. Also
DNA repair mechanisms are less efficient in mitochondria than in nucleus [23], although
mitochondria have most of the DNA repair pathways existing in the nucleus [24]. The
mitochondrial reactive oxygen species (ROS) theory of aging (mitochondrial free radical theory
of aging [MFRTA]) proposed by Harman assumes that free radicals generated in normal
metabolism cause mtDNA mutations and ageing is a result of oxidative damage accumulation.
According to MFRTA, maximum life span can be decreased by mtDNA damage caused by
oxidative stress [25]. Mitochondrial reactive oxygen species (mtROS) may play signaling role
in mitochondrial stress during ageing [26]. It is also suggested that mtDNA mutation accu‐
mulation and mitochondrial dysfunction during aging are a result of decreased activity of
autophagy and mitophagy [27]. Moreover, a study performed on 18 three-generation families
of women shows decline in mtDNA copy number, mitochondrial protein expression, and
oxidative function with age [28]. Oxidative DNA damage and mitochondrial dysfunction lead
to neuronal loss and may play a role in the development of dementia. The decreased level of
antioxidants was observed among dementia individuals [29, 30]. It was suggested that high
levels of ROS and decline in neuronal DNA damage response may be associated with neuronal
dysfunction and cognitive impairment characterized by lower Mini-Mental State Examination
(MMSE) score [31]. Additionally, it is known that oxidative damage leads to frontal-executive
dysfunction [32].
Gene/encoded product Locus Role in aging References
SIRT1
sirtulin 1
10q21.3 Age-related decreased level of SIRT1 is associated
with impaired oxidative stress response and changes in glucose
metabolism. Indirectly may be involved in age-related diseases, for
example, retinal degeneration, hypertension, and cardiovascular
diseases.
[12]
AKT1
protein Kinase B
14q32.32 Decreased level of AKT1 with age alters
regulation of glucose metabolism, apoptosis,
cell proliferation and cell migration, and PI3K/AKT/mTOR pathway.
[13]
CDKN1A
Cyclin-dependent kinase
inhibitor 1 (p21)
6p21.2 Possible promoter of aging due to pro-aging activity of p53.Oxidative
stress increases expression of CDKN1A and overexpression of p21
may be involved in age-related diseases such as atherosclerosis,
amyloidosis, AD, and arthritis.
[14]
[15]
CETP
Cholesterol ester transfer
protein
16q21 Responsible for cholesterol homeostasis in central nervous system.
Decreased level of CETP
results in healthier aging, slower memory decline, less frequency of
dementia, and lower AD risk.
[16]
[17]
FOXO3A
Transcriptional factor
FOXO3A
6q21 Involved in insulin metabolism and insulin/IGF1 signaling pathway.
Protection from oxidative stress and reduction of age-related diseases.
[18]
[19]
IGF-1
Insulin-like growth
factor 1
12q23.2 Decreased level of IGF-1 with age leads to cell senescence. [20]
PON1
Paraoxonase 1
7q21.3 Decreased level of PON1 with age impairs oxidative stress response
and is a risk factor for cardiovascular diseases due to LDL oxidation.
[21]
[22]
Table 1. The role of genes and their encoded products in aging.
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Another mechanism involved in aging is epigenetic alterations. Epigenetics is defined as
molecular traits that are “stably heritable phenotype resulting from changes in a chromosome
without alterations in the DNA sequence.” The epigenetic pathways include DNA methyla‐
tion, histone modifications, and noncoding RNA [33].
The analyses of CpGs methylation changes show that genome-wide global levels of DNA
methylation decrease during aging. Despite this, many promoters of genes which are unme‐
thylated in young gain methylation in old individuals [34, 35]. Other authors [36] suggest that
DNA methylation changes may result in age-associated immune deficiency. It is possible that
hypermethylation is caused by programmed changes, while hypomethylation may be the
result of environmental and stochastic processes. Multiple studies have identified genes
undergoing hyper- and hypomethylation with age. The first group includes genes involved in
process such as cell adhesion, cell-cell signaling, ion transport, neuron differentiation, and
other genes associated with development. The hypermethylated genes are regulated by a
common group of transcription factors, whereas hypomethylated genes are involved in
metabolic process, RNA splicing, regulation of ligase activity and protein ubiquitination,
transmission of nerve impulse, and many others. The hypomethylation in neurons may cause
age-related memory deficits [36, 37]. The abnormal profile of methylation may contribute to
dementia. It is shown that mutation in DNA methyltransferase 1 (DNMT1), gene encoding an
enzyme crucial for methylation, leads to a condition called hereditary sensory and autonomic
neuropathy (HSAN1) with early onset of dementia and hearing loss [38]. Other authors suggest
[39] that changes in methylation may be involved in age-related cognitive functions decline.
Histone modification includes acetylation, methylation, phosphorylation, citrullination,
ubiquitination, SUMOylation, adenosine diphosphate (ADP) ribosylation, deimination, and
proline isomerization, in which the first three are the most-studied topics. Modifications can
change the chromatin structure by histone-histone or histone-DNA interactions. The chroma‐
tin packaging affects many processes such as transcription, repair, replication, and chromo‐
some condensation. Acetylation is associated with activation of transcription, while the result
of lysine methylation can be either activation or repression [40]. Chromatin packaging changes
during aging [41]. It is shown that higher level of histone acetylation facilitates memory and
learning processes; therefore, acetylation decrement may lead to cognitive impairments and
is associated with aging [42]. Also histone methylation may affect the life span; loss of H3K9
trimethylation which results in reduction of heterochromatin is the hallmark of aging [43]. The
acetylation of H4K16 is necessary for maintaining the structure of chromatin and when
impaired, the process of double-strand break repair is less efficient [44]. Subsequently, histone
tail proteolytic cleavage, especially H3, may be involved in aging, but the exact mechanism
remains unclear [45]. Additionally, the decline in histone chaperon levels is observed during
aging and may be the answer for defective DNA repair mechanisms [46].
Both age-related changes in DNA methylation and histone modification alter the experience-
dependent synaptic plasticity in hippocampus by changing the chromatin structure. Thus, it
may be involved in memory loss and learning difficulties. Epigenetic changes may be possible
brain biomarkers of cognitive aging [47].
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4. Genes associated with age-dependent dementia
Several genes are involved in age-dependent dementia. Most of them, such as ABCA7, APOE,
APOC1, BIN1, CASS4, CELF1, CD33, CD2AP, CELF1, CLU, CR1, DSG2, EPHA1, FERMT2,
HLA-DRB5/DBR1, IL1RAP, INPP5D, MEF2C, MS4A6A/MS4A4E, NME8, PCDH11X, PICALM,
PLD3, PTK2B, TOMM40, TREM2, TRIP4, TRPC4AP, SLC24H4-RIN3, SORL1, and ZCWPW1,
are associated with AD, which is the most prevalent cause of dementia in elders [48]. AD affects
24 million people worldwide and accounts for 60–80% of dementia cases [49]. APOE cluster
(APOE, TOMM40) and CLU gene of the genes mentioned above, as well as Aβ cascade genes
(APP, PSEN1, PSEN2), have also been mentioned as linked to memory decline in cognitively
normal adults.
4.1. APP, PSEN1, and PSEN2
Aβ is formed in a process called an amyloid cascade which involves the amyloid precursor
protein (APP), encoded by the APP gene located on chromosome 21. APP is a transmembrane
protein with high expression in developing human neurons. In normal conditions, APP is
truncated by proteolytic enzymes such as α- and β-secretases. However, in individuals
developing AD, APP is processed by an alternative pathway involving γ-secretase. This leads
to the production of the 40–42 amino-acid Aβ peptide. The active subunits of γ-secretase
presenilin 1 and/or 2 are encoded by genes PSEN1 and PSEN2, respectively. So far, 230
clinically significant mutations have been described in APP, PSEN1, and PSEN2 genes;
however, these mutations are very rare and account for around 0.5% of dementia cases.
Moreover, most of these mutations are considered to be associated with a familial form of AD.
On the other hand, asymptomatic carriers of the mutations in Aβ cascade genes demonstrate
significant changes in cognitive functions, advancing with age [48].
4.2. TOMM40, translocase of the outer mitochondrial membrane 40 homolog (TOM40)
TOMM40 is a gene encoding for translocase of the outer mitochondrial membrane 40 homolog
(TOM40). The gene is located on chromosome 19 in a cluster with APOE. Both genes remain
in linkage disequilibrium and are associated with dementia [50]. Most reports concerning the
role of TOMM40 in developing dementia have focused on a variable length poly-T sequence
polymorphism (rs10524523) located in intron 6 [51–53]. The number of deoxythymidine
residues in the rs10524523 polymorphism comprise the so-called “alleles” of the poly-T repeat
as “short” (abbreviated here as S), “long” (L), or “very long” (VL). These remain in strong
linkage with the APOE variants, as the TOMM40 L allele is almost exclusively observed in the
APOE E4 carriers, while TOMM40 S and/or the VL variants are associated with APOE E3 [51–
53]. The poly-T variation in TOMM40 was shown to be significantly associated with the age
of onset of dementia [52]. Moreover, as shown in [51], the TOMM40 poly-T variant may
facilitate the estimation of dementia progression in AD patients, independently from the status
of other dementia loci. They also implied that the genome-wide association studies (GWAS)
signals recorded in the APOE locus may indeed arise from TOMM40.
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It has been suggested that Aβ may exert intracellular toxicity mediated by TOM40, for example,
by affecting the function of cellular power plants—the mitochondria. According to [50], the
mechanism underlying TOM40’s role in dementia involves its ability to uptake Aβ to the
mitochondrion, as Aβ has been found to be co-localized with cristae proteins in the mitochon‐
dria. Subsequently, after absorption the intracellular Aβ would cause increased production of
ROS, thus leading to DNA damage and premature neuronal death.
Several studies have shown that poly-T TOMM40 variation may influence cognitive perform‐
ance in healthy elderly people. The authors of study [54] investigated a cohort of 1613 elderly
volunteers whose cognitive decline was followed for a period of 14 years (range = 12–18 years).
This study showed that the TOMM40 S variant repressed the activity of luciferase assay.
Correspondingly, expression of the S variant was half of that in the VL variant. Moreover, they
observed that the S variant significantly reduced vocabulary ability, diminished age-depend‐
ent vocabulary decline, in subjects as compared to the VL variant carriers. Other authors [55]
conducted longitudinal modeling of a cognitive aging study on a cohort of 639 subjects with
no signs of dementia, aged 21 to 97 years with a known TOMM40 and APOE status. The
volunteers underwent neuropsychological testing every 2 years. This study [55] showed that
the influence of TOMM40 variation on memory decline was particularly visible in subjects
before 60 years of age (p = 0.009), however only in TOMM40 VL/VL carriers whose improve‐
ment after the test-retest was significantly less pronounced than in the S/S and S/VL carriers.
Moreover, the authors performed a neuropsychological examination and testing using the
human analog of the Morris water maze and brain MRI on 59 cognitively normal volunteers,
stratified as S/S, S/VL, and VL/VL carriers. They found that the S/S group performed better on
world-centered navigation (p ≤ 0.004) and world-centered delayed recall (p ≤ 0.014) but not on
self-centered navigation tests. They also found that the TOMM40 variants significantly
influenced the brain structure. The S/S group had a thicker right entorhinal cortex (p ≤ 0.043)
than the S/VL and VL/VL groups, whereas significant thinning of the left entorhinal cortex and
the left posterior cingulate cortex was present only in the VL/VL group (p = 0.043 and p = 0.024,
respectively) as compared to the S/S group [55]. In another interesting study [56], the authors
stratified 117 healthy adults (medium age: 55 years) with the APOE E3/E3 genotype according
to the TOMM40 status into three groups, S/S, S/VL, and VL/VL, and performed memory tests
and structural brain imaging. They found that the asymptomatic carriers of the TOMM40 VL/
VL genotype performed worse on testing of episodic learning and had a smaller volume in the
posterior cingulate as compared to the S/S and S/VL groups [56].
These studies suggest that the TOMM40 role is not limited to decreasing age at the onset of
dementia but may also influence the brain structure and hasten memory decline in cognitively
normal, healthy individuals.
5. Cholesterol, lipoproteins, and dementia
Of the many lipids, cholesterol is believed to play a major role in brain function and develop‐
ment, as the brain contains as much as 23% of the total cholesterol deposits [57]. One of the
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most pronounced groups of genes described as dementia risk factors are involved in the
transport of cholesterol and may be accounted for as apolipoproteins [58]. A misbalanced lipid
metabolism may be associated with memory loss [59]. According to another paper [60],
patients with higher levels of high-density lipoproteins (HDLs) had a decreased risk of
developing dementia at the time of the study and in the future. For patients from the upper
quartile (with a plasma HDL concentration higher than 55 mg/dL), the dementia hazard was
decreased by 60%. Studies on the subjects were continued by several other teams; however,
the obtained results seem to be rather inconsistent [61–67].
Generally, the HDL level is believed to negatively correlate with the prevalence of dementia
in elderly people; however, many studies have implied that HDL influence may be character‐
istic of the VD development [58, 68].
5.1. CLU, apolipoprotein J (apoJ)
Apolipoprotein J (apoJ, also known as clusterin), encoded by the CLU gene, has been shown
to probably be associated with dementia. Genome-wide association studies (GWAS) per‐
formed by authors [69] identified a genetic variation (rs11136000) which was a significant risk
factor of dementia. The role of apoJ in the pathomechanism of AD is not fully understood. It
has recently been shown that apoJ plasma levels positively correlate with the risk of dementia,
as elevated apoJ levels have been reported in the plasma of AD patients as well as in their brain
and cerebrospinal fluid (CSF). The study [70] showed that apoJ plasma, but not CSF, levels are
elevated in AD patients and were a risk factor of dementia (HR 18.6). This biomarker was also
shown to be significantly correlated with cognitive decline in AD patients and reversely
correlated in individuals with mild cognitive impairment (MCI). Moreover, increased plasma
apoJ levels in MCI indicated an amplified risk of further cognitive decline. Furthermore, it was
shown that genetic variation in the CLU region may amplify the influence of personality type
on the performance of declarative memory in older, non-demented adults [71].
5.2. APOE, apolipoprotein E (apoE)
ApoE is encoded by the APOE gene, which is located on the long arm of chromosome 19. It
comprises four exons. Two frequent polymorphisms were described on the last exon: rs7412
and rs429358. These variants encode for three common alleles of APOE: E2, E3, and E4,
encoding for apoE ε2, ε3, and ε4, respectively.
ApoE in physiological conditions is a major cholesterol carrier and one of the most vital
proteins responsible for maintaining cholesterol homeostasis in the brain. ApoE is mostly
synthesized by astrocytes and probably does not cross the blood-brain barrier [72].
A recent study [73] on transgenic rabbit Apoe knockouts (Apoe -/-) showed that apoE is essential
for cholesterol homeostasis under stress conditions. Under normal conditions, the transgenic
animals were able to maintain a stable, physiological level of plasma cholesterol. However,
when the animals were transitioned to a diet with high cholesterol content, its level increased
dramatically (1070 ± 61 mg/dL in apoE KO vs 169 ± 79 mg/dL in the wild type, p < 0.001).
Another study [74] showed that increased content of fat and cholesterol in the diet increased
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apoE production, probably due to transcriptional and posttranscriptional mechanisms. This
suggests that functional apoE is essential for cholesterol regulation in mammals and protects
against diet-induced atherosclerosis. The various variants of APOE have a distinct influence
on apoE function and effect. Studies on humans and in apoE transgenic mice suggest that
lipidation of apoE depends strongly on the APOE genotype, and that apoE ε2 and ε3 are
significantly more lipidated than apoE ε4. Interestingly, cholesterol and proper apoE lipidation
are essential for apoE function in sustaining synapses [75].
A study [76] analyzing the association of plasma and CSF apoE concentrations showed that
the CSF/serum ratios of apoE levels were associated with progression of dementia. Schmidt et
al. observed that “the lower the ratio, the faster the deterioration,” as measured by the MMSE,
instrumental activities of daily living (iADL), or Geriatric Depression Scale (GDS). Subse‐
quently, another study [77] showed that plasma apoE may be a biomarker of dementia, as
patients suffering from memory decline had lowered concentrations of plasma apoE.
The first reports indicating that APOE may be associated with dementia were published more
than 20 years ago. Detailed studies of this gene were carried out mainly in AD; however, the
literature data support APOE influence on memory in people with no symptoms of dementia.
It is believed that APOE E3 is the most common allele in the population and does not modify
the risk of memory decline. The APOE E4 variant was shown to be overrepresented in dementia
patients, especially those with AD [78]. So far, APOE E4 remains the most significant risk factor
of sporadic AD and accounts for 30% of cases [79]. APOE E2 was shown to be associated with
reduced age-dependent cognitive decline. This observation occurred independently of age-
related neuroinflammation and synaptic changes or the Aβ burden [80]. The described effect
may be explained by a higher apoE level in APOE E2 carriers as well as by more efficient Aβ
clearance [81]. Moreover, according to study [75], the effects of APOE E2 and E4 counteract,
and in transgenic mice the introduction of the E2 allele decreased Aβ deposition, while the E4
allele increased the Aβ burden.
According to [82], the most significant APOE effect on the onset of dementia may be observed
in patients over the age of 60 (p = 0.006). This was visible as an accelerated memory decline in
APOE E4 carriers. However, other authors [83] reported that characteristic changes in MRI
may be observed even in healthy infants carrying the APOE E4 allele. According to authors of
[84], the APOE E4 allele is not only responsible for a decline in episodic memory with age in
cognitively normal adults but may also induce impaired olfaction due to deterioration of
medial temporal lobe. This is consistent with the neuroimaging data, suggesting that in non-
demented APOE E4 carriers, mediotemporal atrophy occurs prior to clinical dementia onset.
It is also interesting that multiple studies have confirmed that the TOMM40/APOE locus is
associated not only with the risk of dementia but also with longevity. The GWAS confirmed
that the rs4420638 polymorphism on chromosome 19q13.32 was significantly related to living
longer than >85 years (OR = 0.72, p = 3.40 × 10-36) [85]. Similarly, according to a recent study [86],
with the use of more sophisticated integrative GWAS (iGWAS) method to couple data from
14 meta-analyses, the locus housing APOE and TOMM40 remained significantly associated
with longevity, even when the false discovery rate (FDR) was set at 10%, which indicates that
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the APOE/TOMM40 locus holds the key for healthy senescence without a pathological memory
decline.
6. APOE in a healthy Polish population under 60 years of age
Despite the many years of research, AD remains a disease that is difficult to predict and
diagnose, with few blood-derived biomarkers possible for use in routine clinical setting. As
was stated before, APOE remains the most significant genetic risk factor of AD. This creates a
need for the development of a novel, quick, and reliable method of analyzing the APOE
genotype and the apoE plasma concentration. The role of APOE in the development of
dementia and its influence on longevity in elderly people has been studied by [53]. As per our
knowledge, APOE studies on a younger population in Poland have been neglected and there
are no literature data on association of the APOE genotype and the apoE plasma level in non-
demented Polish adults.
6.1. Aim of the study
In this study, we tried to assess the influence of the APOE genotype and the effect of demo‐
graphic factors on the apoE level in a subset of Polish non-demented volunteers less than 60
years of age.
6.2. Subjects
A total of 83 healthy adults (70 females, mean age: 51.9 ± 7.2; 13 males, mean age: 44.9 ± 11.7)
under 60 years of age with no signs of dementia or other neurological disorders were enrolled
in the study. All participants provided signed, written consent. The research project was
approved by the Bioethical Committee at the Poznan University of Medical Sciences, decision
no. 1031/13, dated May 5, 2013.
6.3. Materials
Each volunteer’s blood was collected on an anticoagulant—K3EDTA (Monovette™ vacuum
system, Sarstedt, USA). A total of 3 ml of blood was immediately aliquoted, then frozen and
stored at −80°C upon nucleic acid isolation. Subsequently, the remaining blood was centri‐
fuged (1400 relative centrifugal force [RCF], 10 min) and the collected plasma was aliquoted
and stored at −80°C.
6.4. Methodology
6.4.1. APOE genotyping
First, a subject’s DNA was extracted from frozen blood using gravity flow microcolumns
(Genomic Micro AX Blood Gravity, A&A Biotechnology, Poland). The DNA concentration was
measured by a microplate spectrophotometer (Take3, Epoch, BioTek, USA) and adjusted to 20
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ng/μL with Milli-Q® water. Subsequently, genotyping was performed according to a modified
mismatch primer method [87]. Briefly, three quantitative polymerase chain reaction (qPCR)
specific to each APOE allele were performed with the use of four different primers (as shown
in Table 2). The qPCR included two steps: primary pre-amplification (15 cycles) with annealing
at 64°C followed by 30 cycles of secondary amplification with annealing at 62°C. The reactions
were performed on a CFX Connect™ Real-Time PCR Detection System (Bio-rad, USA) in 10
μL volumes, with 250 nM primers and 50 ng of genomic DNA using 1× SsoFast™ EvaGreen®
Supermix (Bio-rad, USA). The cycling conditions were: 30 s initial denaturation at 98°C
followed by cycles of 98°C for 5 s and 64 and 62°C for 10 s. The reaction was considered positive
once the products appeared before the 10th cycle of secondary qPCR. The method was
validated by Sanger sequencing in an external laboratory.
Reaction Starter Sequence Annealing
temperature
Product
melting point
APOE E2 APOE112C CGGACATGGAGGACGTGT 62–64°C 91.4°C
APOE158C CTGGTACACTGCCAGGCA
APOE E3 APOE112R CGGACATGGAGGACGTGC 91.6°C
APOE158C CTGGTACACTGCCAGGCA
APOE E4 APOE112R CGGACATGGAGGACGTGC 91.8°C
APOE158R CTGGTACACTGCCAGGCG
Table 2. Starters used for genotyping of APOE.
6.4.2. ApoE quantification
Determination of the plasma apoE concentration was performed by the enzyme-linked
immunosorbent assay (ELISA) method. The analysis was performed according to the manu‐
facturer’s protocol (Human apoE ELISA Kit, Mabtech, Sweden) using 10,000× diluted plasma
samples. Absorbance was measured by an EPOCH microplate reader (BioTek, USA). The
concentrations were calculated from a four-parametric standard curve (R = 0.998) by Gen5 ver.
2.01 software (provided with the reader).
6.5. Results
Our study on Polish subjects showed that the observed genotype frequencies of APOE are in
line with the Hardy-Weinberg equilibrium (p = 0.9365). The dominating allele was APOE E3
(83.7%) and the least common allele was APOE E2 (3.0%), as is shown in Figure 1. Interestingly,
we did not observe any APOE E2/E2 homozygotes, as is shown in Table 3.
Our results indicate that the apoE plasma concentration depends on the APOE genotype (one-
way analysis of variance [ANOVA], p = 0.021). Generally, in APOE E3/E3 carriers we recorded
the highest mean concentrations of apoE, while in the APOE E4/E4 homozygotes we recorded
the lowest mean concentrations. In females with the APOE E2/E3 allele, the concentration of
apoE was slightly lower than in the E3 homozygotes. Interestingly, in a single case of an
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E2/E4 carrier we observed an increased level of plasma apoE. Subsequently, the plasma apoE
concentration in APOE E3/E3 carriers was higher in males than in females. Conversely, in
APOE E3/E4 carriers the recorded apoE concentration was higher in females. Hence, the
decrease in apoE due to the APOE E4 genotype was more pronounced in males than in females
(41% vs 16%), as shown in Table 3. Overall, the apoE concentration was insignificantly higher
in males than in females (2.54 vs 2.24 mg/dL; p = 0.194, Student’s t-test). The observed positive
trend of increasing apoE in older individuals did not reach statistical significance (r = 0.201, p
= 0.0687; Pearson correlation coefficient). However, after stratification according to gender, we
observed significant correlation of the apoE plasma level and age in females (r = 0.348, p =
0.00128; Pearson correlation coefficient). The concentrations of apoE stratified according to
APOE status, gender, and age are shown in Table 4 and Figure 2, respectively.
Figure 1. Frequencies of APOE alleles in Polish, cognitively normal volunteers under 60 years of age.
Genotypes APOE E2/E2 APOE E2/E3 APOE E3/E3 APOE E3/E4 APOE E4/E4 APOE E2/E4
Observed frequencies 0
0.0%
4
4.8%
58
69.9%
19
22.9%
1
1.2%
1
1.2%
Expected frequencies 0.08
0.1%
4.19
5.0%
58.20
70.1%
18.42
22.2%
1.40
1.8%
0.66
0.8%
Note: Hardy-Weinberg equilibrium calculations, p = 0.9365, n = 83.
Table 3. Hardy-Weinberg equilibrium calculations of APOE variants in Polish, cognitively normal volunteers less than
60 years of age.
Gender APOE E2/E3 APOE E2/E4 APOE E3/E3 APOE E3/E4 APOE E4/E4
Female 1.98 ± 0.67 2.91 2.35 ± 0.78 2.02 ± 0.52 0.69
Male – – 2.91 ± 0.63 1.72 ± 0.22 –
Combined 1.98 ± 0.67 2.91 2.43 ± 0.79 1.95 ± 0.49 0.69
Note: Mean concentration ± SD (mg/dL) or (single result).
Table 4. Mean plasma apoE concentration (mg/dL) in Polish, cognitively normal volunteers under 60 years of age
stratified according to gender and APOE genotype.
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Figure 2. Mean apoE plasma concentration (mg/dL) in Polish, cognitively normal volunteers under 60 years of age
stratified according to gender and age.
6.6. Discussion
As was stated before, the APOE E4 allele is associated with increased risk of developing
dementia.
According to our results, the APOE E3 genotype was the most prevalent genotype in the
studied group, while the E2 genotype was the least common. Similar results were reported in
the Polish population [53].
Our study shows that APOE E4 variant is associated with a decreased concentration of plasma
apoE in cognitively normal Polish volunteers less than 60 years of age. Our results are
supported by the results of other authors [77], who analyzed plasma apoE concentrations and
APOE status in a cohort of 75,708 participants in the Copenhagen General Population Study
and the Copenhagen City Heart Study. The authors also showed that apoE is dependent on
the APOE genotype, as they found substantial differences in plasma apoE concentrations
between carriers of distinct APOE genotypes. However, contrary to our results, in their study
the highest level of apoE was observed in APOE E2 homozygotes and decreased in E4 carriers
in a dose-dependent manner: E2/E2 > E2E3 > E2/E4 > E3/E3 > E3/E4 > E4/E4. The plasma
concentration of apoE in E4/E4 homozygotes was up to 65% lower as compared to APOE
E2/E2 carriers. This partial incompatibility with our results may be explained by the utilization
of various methods: the authors used the nephelometry and turbidimetry methods, whereas
we used the well-established ELISA method. In another study [88], the authors showed that
apoE concentrations in plasma apoE increased with age in a healthy population. We observed
a similar trend; however, it was significant only in the female group.
The plasma concentration of apoE may be a valuable dementia biomarker because it is easily
available and, according to literature data, decreased apoE may be a risk factor for developing
dementia. The above-mentioned Australian follow-up cohort study, comprising mostly
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Caucasian subjects, showed that the reduced apoE plasma level may be a predictor of a
transition from MCI to AD. Moreover, the plasma apoE concentration correlates positively
with cognitive function, and patients with a lower apoE level tend to perform worse in
neuropsychological tests assessing spatial memory and language abilities [89].
Hence, the assessment of the plasma apoE concentration and the APOE status may give
valuable information to physicians trying to predict the rate of cognitive decline in the course
of dementive disease as well as in normally ageing adults and elderly persons.
7. Summary
The appearance of dementia in old age is influenced by both biochemical and genetic factors
leading to structural disorders in the brain of elderly persons. The level of Aβ is mentioned
among the other biochemical factors associated with dementia. The deposition of Aβ in the
brain is controlled by APOE and by genes associated with the amyloid cascade (APP, PSEN1,
and PSEN2). Subsequently, Aβ toxicity is modified by the TOMM40. In the elderly, also
abnormal cholesterol, glucose levels, and the weakening of protective and repair mechanisms
leading to the generation of ROS (mediated, e.g. by PON1) may cause a reduction in cognitive
functions. However, the role of genes associated with longevity (e.g. FOXO3A, CETP) and
normal aging (e.g. SIRT1, AKT1, CDKN1A) is not clearly defined in the occurrence of diseases
typical for this age group, as shown in Figure 3.
Finding a way to control the genetic factors and their protein products may contribute to the
prevention of diseases of old age, including depression and dementia, and to improve the
quality of life of elderly people.
Figure 3. The genetic and biochemical factors associated with normal aging and dementia; β-amyloid—Aβ.
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